[May 20 (Wed) 16:00] Akira Noguchi, who managed major Japanese and US pharmaceutical companies in Europe, America, Asia, China, and Japan, discusses "Winning Prospects" of Global Expansion Strategy and Optimal Market Selection

"Connecting knowledge and challenges" is the mission of VisasQ Inc. (hereinafter referred to as "the Company"), which operates a global knowledge platform. The Company will host a free online seminar on "Winning Prospects of Global Expansion Strategy and Optimal Market Selection," featuring Akira Noguchi, Representative of Global Mindset, on May 20 (Wednesday) at 16:00.

◆ Details and Registration: https://visasq.co.jp/seminar/vs202605200347?utm_source=prtimes&utm_medium=referral&utm_campaign=seminar_expert_20260520

◆ Background The Company operates a global knowledge platform that matches business-savvy individuals with companies for various initiatives such as new business development, DX promotion, and overseas expansion. It offers matching services utilizing a knowledge database of over 800,000 experts both in Japan and internationally (as of February 2026). Companies undergoing transformation utilize this platform to access external knowledge and primary information based on individuals' real-world experiences in their industry and work, supporting business creation for over 2,200 clients. (Case studies: https://visasq.co.jp/case) Additionally, for companies engaged in business development, the Company hosts free online seminars inviting "professionals in the field" on themes such as new business development and business trends, providing useful information for corporate transformation and innovation creation.

◆ Seminar Introduction This seminar will feature Akira Noguchi, Representative of Global Mindset. Mr. Noguchi possesses extensive knowledge in this domain. Below is an overview of the lecture content: The sense of urgency that "we must expand into overseas markets" is now common among all Japanese companies. However, when devising the "sales and monetization" strategy, are companies making decisions based solely on examples from other companies or superficial market sizes? As of 2026, the US and European drug pricing systems, post-Trump administration, have become so complex that it is said "only a handful of Japanese people can provide answers," rendering past success formulas obsolete. A common pitfall for many Japanese companies is underestimating PMI (Post-Merger Integration), treating market access as a post-process and considering "acquisition as the end." When companies advance with ambiguous objectives for "products, sales channels, and technology," relying only on financial calculations, they lack persuasiveness to local payers and struggle with monetization. Such "strategic misalignment" becomes a fatal blow, stagnating the globalization of the company itself. This seminar will welcome Akira Noguchi, who has extensive top management experience in Europe, America, and China, to unravel strategic market selection derived from "three types of global expansion." Mr. Noguchi advocates for building "integrated operations" that align a company's vision with its assets. He will clarify the ironclad rules of launch sequences in the US, Europe, and Japan, and how to approach the transformed Chinese market, as well as the principles of "prioritization" and "speed of PMI" that only Mr. Noguchi can articulate. In this opaque era ahead, what is the "true logic" for R&D and marketing departments to reliably deliver "good drugs" to patients and maximize profits? It is only established through "clear commitment from management" to translate on-site efforts into results, and a "consistent strategy" that considers the company's current position. Mr. Noguchi will thoroughly explain the direction for fundamentally improving global competitiveness based on his experience. Please join this opportunity to grasp "concrete strategies and measures" to accelerate corporate globalization, going beyond mere investment success or failure.

Topics to be discussed on the day 1. "Three types" of globalization and the ideal state Selection of the optimal entry method based on the company's resources and vision. 2. Established "launch sequence" in the US, Europe, and Japan Market entry order to maximize development speed and quickly secure profits. 3. Effectiveness of PMI by purpose Key points for integration speed and organizational management vary depending on "what was acquired." 4. The path forward for future pharmaceutical companies.

Recommended for ・Management, corporate planning, and overseas business managers of Japanese pharmaceutical and healthcare companies. ・Leaders in business development and licensing divisions of healthcare and pharmaceutical industries. ・Those in global marketing and medical divisions responsible for strategies considering commercialization.